Skip to main content

Merus N.V. (MRUS) Stock

Merus N.V. Stock Details, Movements and Public Alerts

Stock Details

Merus N.V. (MRUS), a prominent company in the healthcare sector within the biotechnology industry, is based in Netherlands and primarily trades on the NGM.Currently, the stock is trading at $90.00. Over the past 52 weeks, it has ranged between $33.19 and $97.14. This places the current price at 92.6% of its 52-week high and 171.2% above its 52-week low. 0The 14-day Relative Strength Index (RSI) stands at 70.30, suggesting overbought conditions. The stock is currently trading below its 50-day moving average of $95.81 by 6.06%. Similarly, it is above its 200-day moving average of $67.58 by 33.18%. The MACD histogram is -0.12, indicating bearish momentum (MACD Line: 0.54, Signal Line: 0.66).

52-Week Range

$97.14 - $33.19

-7.35% from high · +171.17% from low

Avg Daily Volume

1,042,956

20-day average

100-day avg: 1,800,680

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-21.04

Price to Book

9.49

EV/EBITDA

-18.24

EPS (TTM)

-$5.28

Price to Sales

129.86

Beta

1.06

Similar volatility to market

Q:How is MRUS valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is MRUS's risk profile compared to the market?
With a beta of 1.06, Merus N.V. is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 9.49 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-794.06%

EBITDA

$-368,772,000

Return on Equity

-51.57%

Return on Assets

-26.53%

Revenue Growth (YoY)

3.20%

Q:How profitable and efficient is MRUS's business model?
0 The operating margin of -794.06% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -51.57% and ROA at -26.53%, the company achieves moderate returns on invested capital.
Q:What are MRUS's recent growth trends?
Merus N.V.'s revenue grew by 3.20% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$7.4B

Revenue (TTM)

$56.61M

Revenue/Share (TTM)

$0.80

Shares Outstanding

75.85M

Book Value/Share

$10.22

Asset Type

EQUITY

Q:What is MRUS's market capitalization and position?
Merus N.V. has a market capitalization of $7.4B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 75.85M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does MRUS's price compare to its book value?
Merus N.V.'s book value per share is $10.22, while the current stock price is $90.00, resulting in a price-to-book (P/B) ratio of 8.81. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$97.00

7.78% upside potential

Analyst Recommendations

Strong Buy

0

Buy

2

Hold

14

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for MRUS?
16 analysts cover MRUS with 13% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $97.00 implies 7.8% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on MRUS?
Current analyst recommendations:02 Buy, 14 Hold, 00The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Dec 28, 2025, 02:14 AM

Technical Indicators

RSI (14-day)

70.30

Overbought

50-Day Moving Average

$95.81

-6.06% below MA-50

200-Day Moving Average

$67.58

33.18% above MA-200

MACD Line

0.54

MACD Signal

0.66

MACD Histogram

-0.12

Bearish

Q:What does MRUS's RSI value tell investors?
The RSI (Relative Strength Index) for MRUS is currently 70.30, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being below the 50-day moving average, this shows mixed signals requiring careful analysis.
Q:How should traders interpret MRUS's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.54 below the signal line at 0.66, with histogram at -0.12. This bearish crossover indicates downward pressure. The 50-day MA ($95.81) is above the 200-day MA ($67.58), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Dec 28, 2025, 12:56 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for MRUS and get notified when the price changes.

Stay Ahead of the Market with Merus N.V. Alerts

Set up price alerts for Merus N.V. and get notified instantly when the price hits your target. Never miss an important price movement again.